A5101890140- Cancer Treatment and Pharmacology
- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Pneumocystis jirovecii pneumonia detection and treatment
- Cancer Cells and Metastasis
- HIV Research and Treatment
- Lung Cancer Treatments and Mutations
- Cancer, Hypoxia, and Metabolism
- Circadian rhythm and melatonin
- Ubiquitin and proteasome pathways
- Pregnancy and Medication Impact
- Monoclonal and Polyclonal Antibodies Research
- DNA Repair Mechanisms
- Cancer, Lipids, and Metabolism
- HER2/EGFR in Cancer Research
- Social Sciences and Policies
- Chronic Lymphocytic Leukemia Research
- Genetics, Aging, and Longevity in Model Organisms
- Telomeres, Telomerase, and Senescence
- Ferroptosis and cancer prognosis
- Cancer Genomics and Diagnostics
- Hedgehog Signaling Pathway Studies
- Peptidase Inhibition and Analysis
Spanish National Cancer Research Centre
2011-2024
Universidad Europea
2020-2022
Hospital Universitario Infanta Sofía
2022
Instituto de Salud Carlos III
2011-2022
Centro de Investigación Biomédica en Red
2022
Hospital Universitario Fundación Alcorcón
2014-2015
Centro de Investigación del Cáncer
2013
Azienda Ospedaliera Universitaria Pisana
2012
Centro Nacional de Investigaciones Científicas
2012
Institute of Oncology Ljubljana
2012
<h3>Objectives</h3> The tumour stroma/microenvironment not only provides structural support for development, but more importantly it cues to cancer stem cells (CSCs) that regulate their self-renewal and metastatic potential. This is certainly true pancreatic ductal adenocarcinomas (PDAC), where tumour-associated fibroblasts, stellate immune create an abundant paracrine niche CSCs via microenvironment-secreted factors. Thus understanding the role stroma play in PDAC development CSC biology of...
Abstract The mechanistic target of rapamycin complex 1 controls cellular anabolism in response to growth factor signaling and nutrient sufficiency signaled through the Rag GTPases. Inhibition mTOR reproducibly extends longevity across eukaryotes. Here we report that mice endogenously express active mutant variants RagC exhibit multiple features parenchymal damage include senescence, expression inflammatory molecules, increased myeloid inflammation with extensive inflammaging a ~30% reduction...
Human epidermal growth factor receptor 2 (HER2) amplification is frequent in ductal carcinoma situ (DCIS) of the breast and associated with poorly differentiated tumors adverse prognosis features. This study aimed to determine molecular effects HER2 inhibitor lapatinib patients positive DCIS. Patients DCIS received 1,500 mg daily for four consecutive weeks prior surgical resection. Magnetic resonance imaging (MRI) was used changes tumor volume. The on signaling (PI3K/AKT RAS/MAPK pathways),...
The present study sought to describe the use of generic drugs and single-tablet regimen (STR) de-simplification for treatment human immunodeficiency virus (HIV) infection among 41 hospitals from cohort Spanish HIV/AIDS Research Network (CoRIS). In June 2018, we collected information on when antiretroviral (ARVs) were introduced in different hospitals, how decisions them made, was provided patients. Most nine available ARVs Spain by 2018 had been at least 85% participating except zidovudine...
Abstract Background The aim of this study was to investigate the effectiveness and tolerability combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from cohort Spanish HIV/AIDS Research Network (CoRIS). Methods Treatment-experienced starting treatment with EVG/COB/TFV/FTC DRV during years 2014–2018 more than 24 weeks follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or...
3543 Background: Chemotherapy (Ch) options for patients (pts) with colorectal cancer (CRC) have increased in the last years. However, there are no validated prospective molecular markers CRC to select which agents better treat any individual case. The aim of this study was determine efficacy terms progression free survival (PFS) a biomarker panel guide treatment selection setting. Methods: Treatment naive, ECOG 0-1, metastatic pts were accrued. Pts prospectively analyzed predefined set 10...
11033 Background: FVB MMTV PyMT is a great mouse model for studying LBC due to its stochastic nature, immune system preservation, natural growth kinetics and ER/HER2 status. We approached the transcriptomic (T), proteomic (P), phospho-proteomic (P-P) metabonomic (M) layers of regulation tumor phenotype attempting unravel mechanisms resistance antiangiogenic drugs (ADs) find new targets. Methods: Treatments started when tumors measured 0,1cm 3 ; with VEGFR/PDGFR inhibitor BIBF 85mg/kg/day;...